- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: October 10, 2024
- Last Updated: August 20, 2026
TL;DR: Everything an ICL Decision in London Involves, on One Page
If you are searching for ICL surgery in London, you are probably weighing seven questions at once: am I suitable, why ICL rather than laser, what does the operation involve and what is recovery like, what are the risks, who should operate, what does it cost and what is included, and what happens afterwards. This page answers each properly, then answers the questions patients actually ask me across the desk, and hands you to the fuller treatments where they exist. It is written so that a patient who has never heard of Blue Fin Vision® can finish it with enough understanding to decide whether to book.
1. Am I Suitable for an ICL?
An Implantable Collamer Lens is a soft phakic lens placed in the posterior chamber of the eye, behind the iris and in front of your natural crystalline lens, which stays in place and keeps working. Modern designs incorporate a central port that lets the eye’s own fluid circulate through the lens, and the published record for effectiveness and safety, from the original FDA trial through to modern central-port reviews, is strong. ¹ ² ³
Suitability rests on more than a prescription range. A serious assessment establishes that your refraction is stable; that your anterior chamber anatomy can physically accommodate the lens with an appropriate vault, which is why internal measurement rather than external estimation is required; that your endothelium is healthy, recorded as a baseline cell count because the endothelium has very limited regenerative capacity in vivo; that your natural lens is clear, since early lens change points towards lens surgery instead; that your retina is healthy, particularly in higher myopia; that your ocular surface is assessed honestly, because an ICL should not be presented as a treatment for dry eye itself; and that your expectations match what the optics can deliver. Typical candidates are adults with stable prescriptions, often with higher myopia or corneal parameters that constrain safe laser ablation, but the list above is the real test, and some patients fail it. A credible ICL assessment must be capable of ending with a recommendation not to proceed when another option, or no surgery, is better for the patient.
2. ICL or Laser?
Sometimes it should not be an ICL. Laser remains excellent for suitable corneas, and the decision logic is specific rather than generic: corneal thickness and topography, because laser removes tissue and the ICL does not; prescription magnitude, because very high corrections favour the implant’s optical quality; ocular surface status, which laser can aggravate; age and lens status, because an ageing lens in the late 40s or 50s often makes lens replacement the honest recommendation instead; ⁴ and reversibility, because the ICL is designed to be removable while laser is not. Screening for corneal risk remains fundamental whichever road is taken. ⁵ Because Blue Fin Vision® offers all three pathways, the recommendation follows your eye, not our equipment.
3. What Does Implantable Collamer Lens Surgery Involve, and What Is Recovery Like?
Also known as implantable collamer lens surgery, ICL surgery is a relatively brief day-case procedure under anaesthetic drops. The folded lens is introduced through a small opening at the edge of the cornea, unfolds inside the eye, and is positioned behind the iris in front of your natural lens; in routine cases there are no sutures. Most patients notice a substantial improvement quickly, with vision refining over the early weeks as the eye settles, and early reviews confirm three things: that the measured vault matches the predicted one, that intraocular pressure is normal, and that recovery is on course. Normal life, including sport and air travel, resumes on your surgeon’s advice after the early recovery period.
4. What Are the Risks of ICL Surgery, Honestly?
ICL surgery has a strong published safety record across FDA trials, meta-analysis and modern central-port reviews, ¹ ² ³ and honest risk discussion is part of what you are paying for. The recognised issues are specific: a vault that settles too low or too high, whose clinical significance depends on its degree and what is happening elsewhere in the eye, which is why vault is measured and followed rather than assumed; rotation of a toric lens away from its axis, which reduces the astigmatic correction and can be addressed by repositioning; early pressure rises, which have defined management; endothelial cell change over the years, which is why a recorded baseline and monitoring at defined intervals matter, with ten-year central-port data reporting losses of approximately 3.8% to 4.5% in low- and normal-vault eyes; ⁶ the small possibility of exchange, 1.1% in a recent 961-eye series; ⁷ and, like all intraocular surgery, rare but serious complications such as infection, which is one reason theatre standards and an accessible urgent pathway are provider-level questions. None of this argues against the operation. It argues for choosing the system around it carefully.
5. Which Surgeon and Private Eye Clinic in London?
When choosing a private eye clinic in London, the surgeon question and the provider question are different, and both have dedicated answers. For the surgeon, evaluate ICL-specific evidence: sizing method and vault record, endothelial follow-up, toric planning, exchange and removal capability, and audit culture; the full framework, including the questions table, is in Who Is the Best ICL Surgeon in London? For the provider, apply the Year-20 Test in Best Place to Get ICL Surgery in London?: who monitors you in year ten, who removes the lens if ever needed, and what is written down today about the eventual cataract transition.
6. What Does It Cost, and What Is Included?
Pricing is transparent and confirmed at consultation, with current figures on the ICL costs page. The comparison discipline is to compare like with like: a headline price whose pathway ends at the final review is not the same product as one that includes written enhancement coverage and structured lifetime monitoring. Ask every provider which lifecycle elements are included and which are charged when needed, and ask to see the written policy before surgery; provider policies vary, and enhancement may be included for a defined period, subject to eligibility, charged separately or handled under provider-specific terms. At Blue Fin Vision®, enhancement for eligible self-pay ICL patients is fully covered within 24 months under the Enhancement Policy, with no cost-sharing, in writing before surgery. The inclusion questions worth asking anywhere: is the sizing consultation and measurement set included; how many postoperative reviews are covered; what monitoring exists after year one and at what cost; what are the enhancement terms; what would an exchange cost if ever needed; and is there any written position on the eventual cataract pathway? A complete answer to those six questions is rarer than a low headline price, and worth more.
7. What Happens Afterwards, for Decades?
Here is the fact that should shape your entire choice of provider: an ICL is not an event. It is a decades-long relationship. The lens sits inside your eye, in front of your natural lens, and it needs to be respected for as long as it is there: the vault, the space between ICL and natural lens, should be checked, and your corneal endothelial cell count monitored over the years. ¹ And if, in later life, your natural lens develops a cataract, the ICL is removed as part of the transition to cataract surgery and an intraocular lens. Providers differ substantially in what happens after routine postoperative follow-up: ask specifically what monitoring is offered after year one, how long it continues and whether it is included in the original fee. The Blue Fin Vision® pathway is designed for the entire life of the lens.
Concretely, at Blue Fin Vision®: early reviews check the measured vault against the predicted one; structured lifelong vault and endothelial monitoring then runs at defined intervals under the ICL Lifetime Monitoring Protocol™, because long-term follow-up shows vault can change gradually over the years; ⁶ repositioning, exchange and removal sit within our own surgical pathway; and the eventual ICL-to-cataract transition is written into the Blue Fin Vision® Advantage.
What ICL Patients Usually Ask Me
Can I Feel the Lens?
No. It sits behind the iris, bathed in the eye’s own fluid, with no contact with the cornea or eyelids, and there is nothing to handle or maintain.
Can It Move?
The ICL sits stably in the posterior chamber. The clinically relevant version of this question concerns toric lenses, where rotation away from the intended axis reduces the astigmatic correction and can be addressed by repositioning; ask your surgeon how that would be handled.
Can It Be Removed?
Yes, by design, which is one of the ICL’s genuine virtues. It is also rarely necessary: in a recent high-volume series of 961 EVO ICL eyes, the size-related exchange or explant rate was 1.1%. ⁷
Will I Still Develop Cataracts?
The ICL does not stop your natural lens ageing, so like the rest of the population you may develop cataract in later life, at which point the ICL is removed as part of the transition to cataract surgery. What matters is that your provider has a written plan for that day.
What Happens if My Prescription Changes?
A symptomatic residual or later refractive error may, where clinically appropriate, be managed with corneal refractive enhancement or, in selected circumstances depending on the cause, ICL repositioning, exchange or another refractive strategy. Different problems have different solutions, and the pathways should exist in writing.
Does an ICL Cause Dry Eye?
The ICL does not remove corneal tissue, which is one reason it can suit patients for whom laser is less attractive, but it is not a treatment for dry eye, and surface symptoms after any eye surgery deserve assessment as what they are: a surface problem.
Can I Exercise, and Can I Fly?
Yes to both, after the early recovery period your surgeon defines. Normal life, including sport and air travel, is the point of the operation, and your reviews will confirm when each activity resumes.
How Long Does Vision Take to Settle?
Most patients notice a substantial improvement quickly, with vision refining over the early weeks as the eye settles and any surface effects resolve; your early reviews track exactly this.
What Happens at Long-Term Monitoring?
Vault measurement, endothelial cell count against your recorded baseline, pressure and lens checks, at defined intervals, so that year ten is interpreted against year zero rather than guesswork.
Ready?
Book a paid consultation with the consultant-led team at Blue Fin Vision® to discuss your options. With locations across London, Hertfordshire and Essex, the process starts with your own eyes: measurement first, recommendation second.
References
- Packer M. The Implantable Collamer Lens with a central port design: review of the literature. Clin Ophthalmol. 2018;12:2427-2438. PMID: 30568421.
- Packer M. Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lens. Clin Ophthalmol. 2016;10:1059-1077. PMID: 27354760.
- Sanders DR, Doney K, Poco M; ICL in Treatment of Myopia Study Group. United States Food and Drug Administration clinical trial of the Implantable Collamer Lens (ICL) for moderate to high myopia: three-year follow-up. Ophthalmology. 2004;111(9):1683-1692. PMID: 15350323.
- Maldonado MJ, de Salazar Campos A, Castro Machado A. Indications and risk factors in refractive lens exchange: outcomes and special cases (extremes hyperopes and myopes). Arch Soc Esp Oftalmol (Engl Ed). 2026 Jul 20:502616. doi:10.1016/j.oftale.2026.502616. PMID: 42476410.
- Randleman JB, Woodward M, Lynn MJ, Stulting RD. Risk assessment for ectasia after corneal refractive surgery. Ophthalmology. 2008;115(1):37-50. PMID: 17624434.
- Alfonso-Bartolozzi B, Fernández-Vega-Cueto L, Lisa C, Palacios A, Madrid-Costa D, Alfonso JF. Ten-year follow-up of posterior chamber phakic intraocular lens with central port design in patients with low and normal vault. J Cataract Refract Surg. 2024;50(5):441-447. doi:10.1097/j.jcrs.0000000000001379. PMID: 38085219.
- Hirabayashi M, Virdi G, Nasser T, Libfraind L, Zapata EA, Abramson AJ, Parkhurst G. ICL exchanges or explants due to sizing in a United States high volume center. Clin Ophthalmol. 2025;19:2609-2614. doi:10.2147/OPTH.S528280. PMID: 40800717.
ABOUT THE AUTHOR
Mr Mfazo Hove
Consultant Ophthalmic Surgeon
MBChB MD FRCOphth CertLRS
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with experience spanning more than 57,000 procedures. He completed 6.5 years of specialist training at Moorfields Eye Hospital and served for five years as a consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust. He is the founder of Blue Fin Vision®, a consultant-led private ophthalmology practice operating across London, Essex, and Hertfordshire. His clinical expertise encompasses advanced cataract surgery, refractive lens replacement, laser vision correction, and implantable Collamer lenses (ICL).
A ZEISS Key Opinion Leader, Mr Hove is a respected international speaker with five invited engagements across seven cities in 2026:
- ZEISS China tour (Changsha, Shanghai, and Hangzhou, April – ZEISS APAC User Meeting)
- RCOphth Annual Congress – May – Manchester
- ZEISS EMEA User Meeting (Istanbul)
- ZEISS Lausanne User Meeting (Lausanne)
- European Society of Cataract and Refractive Surgeons Annual Congress (ESCRS, London)
